Navigation Links
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
Date:11/21/2007

REINACH, Switzerland, November 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the results of a Phase I trial investigating the possible interaction between intravenous iclaprim and warfarin. Warfarin is widely used for the prophylaxis of thrombosis and embolism and its dosing needs to be well-controlled.The drug-drug interaction study comprised 24 healthy volunteers and was performed in Germany. Dosing of warfarin with and without pre- and co-administration of iclaprim (1.6 mg/kg infused over 60 minutes) was investigated.

Administration of intravenous iclaprim at this supra-therapeutic dose was assessed to be safe for clinical applications. It had no significant effect on the pharmakonetics and pharmacodynamics of warfarin. Moreover, the trial results again confirm the good safety and tolerability profile of iclaprim.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The results of this Phase I study are very positive, showing that iclaprim has no significant effect on the pharmacokinetics of warfarin, which is widely used in the targeted patient population. The results expand the experience gathered in an earlier Phase I study in which the interaction between ketaconazole and iclaprim was investigated. In summary, iclaprim's drug-drug interaction profile looks favourable. This is of great importance as iclaprim is expected to be administered to patients with significant co-morbidities and receiving several other medications. These Phase I data add substantial weight to the NDA package that we intend to file shortly with the U.S. Food and Drug Administration for intravenous iclaprim in its first indication: complicated Skin and Skins Structure Infections (cSSSI)."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... CIRENCESTER, England , September 29, 2014 /PRNewswire/ ... tighter margins and greater competition to transform network ... brand   ProLabs , ... infrastructure products, announced today the findings of their ... Optical Communications (ECOC) with top optical communications professionals ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
(Date:9/29/2014)... , Sept. 29, 2014 CytRx ... research and development company specializing in oncology, today ... (FDA) has granted multiple Orphan Drug Designations for ... indications: glioblastoma multiforme (GBM), small cell lung cancer ... of the widely-used chemotherapeutic agent, doxorubicin. ...
Breaking Biology Technology:SQI Diagnostics Announces New Chairman of Board of Directors 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... , LANSING, Mich., June 18 Fortune Magazine has ... in its annual list of the "40 best stocks to retire ... 40 list in 2002, stating: "We wanted to assemble a diversified, ... that could soar when the market did but also hold steady ...
... June 18 Environmental Tectonics Corporation,s (OTC Bulletin Board: ... the sale of an additional BARA-MED(R)XD monoplace hyperbaric oxygen ... The state-of-the-art monoplace chamber is among the first ... Oklahoma. , , Hyperbaric chambers are used ...
... FRANCISCO, June 18 Burrill & Company, a San ... Venture Capital, Private Equity, Merchant Banking and Media, is ... firm as Managing Director, Merchant Banking. Shawn will assist ... and capital raising transactions. In addition, Shawn will make ...
Cached Biology Technology:Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 3Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 4Shawn Cross Joins Burrill Merchant Banking 2Shawn Cross Joins Burrill Merchant Banking 3
(Date:9/29/2014)... A species of gut bacteria called Clostridium ramosum , ... weight. The work is published this week in mBio ... Microbiology. , A research team from the German Institute ... human gut bacteria including C. ramosum gained weight ... C. ramosum were less obese even when consuming ...
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
(Date:9/29/2014)... with children at home should use ventilation when cooking ... are recommending, after a new study showed an association ... and chronic bronchitis. , "In homes where a gas ... and wheezing is higher than in homes where a ... an associate professor in the College of Public Health ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3
... University of Alberta have pinpointed a genetic marker for sporadic ... in Caucasians., Researchers have identified many genetic markers for familial ... for 80 per cent of all cases. Sambasivarao Damaraju, a ... researcher at the Cross Cancer Institute, worked with his team ...
... a novel method of analyzing genetic variations in families, ... genetic variations affecting related biochemical processes may team up ... findings, reported May 28 in Translational Psychiatry , ... and schizophrenia, and may lead to a genetic test ...
... Osteoporosis Foundation,s key regional meeting in Hong Kong ... enriching scientific programme of direct relevance to your ... experts from around the world. http://www.iofbonehealth.org/hongkong-2013/ ... Plenary sessions devoted to epidemiology, ...
Cached Biology News:U of A medical researchers ID genetic marker for sporadic breast cancer 2Family studies suggest rare genetic mutations team up to cause schizophrenia 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Luminex 100 IS System is a compact ... that integrates lasers, optics, fluidics, a controller, advanced ... This powerful, compact lab analysis system includes the ... Also, it has a DMF file at the ...
... gradient system is ideal for routine binary separations. ... sensitive Adept CE 4201 UV-Visible variable wavelength detector. ... provided by the two highly accurate and ... 4100 solvent delivery pumps., Chromatograms may be plotted ...
... Hep G2 cells were cultured in Minimum Essential ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: